Crown Equity Holdings Inc. is publicly traded with the symbol CRWE. The Company primarily provides and offers advertising, branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. For list of services offered click here

Change City

VANCOUVER, BC / CRWEPRESSRELEASE / September 11, 2015 /Discovery Harbour Resources Corp. (CVE:DHR) (“Discovery” or the “Company”) today announces that it has closed on the extension of 11,000,000 warrants (each, a “Warrant“) issued in connection with the Company’s private placement that closed in September 2013. In consideration of the extension, the warrant holders paid to the Company an extension fee of $0.01 per warrant. The Warrants were exercisable until September 10, 2015, and the expiry date has been extended to December 31, 2016. All other terms of the Warrants, including the exercise price of $0.20, remain the same.

Of the warrants issued, 10,000,000 Warrants are held by Richard Gilliam, a holder of more than 20% of the outstanding common shares of the Company, and 1,000,000 Warrants are held by Westwood Tall Oaks LLC, a trust over which Mr. Gilliam has control and direction. The holders of the remaining 1,217,000 Warrants issued in connection with the September 2013 private placement chose not to extend their warrants by paying the extension fee.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Discovery Harbour Resources Corp.

###

The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.